Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Recruiting 4Terminated 1

Sponsor Class

INDUSTRY 7OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 3Tumor-Agnostic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Neoplasm Metastasis 1Carcinoma, Lobular 1Brain Neoplasms 1

Interventions

Cyclophosphamide 2040Radiotherapy 1854Cisplatin 1820Carboplatin 1530Gemcitabine 1432Paclitaxel 1289Bevacizumab 1267Docetaxel 1200pembrolizumab 1196Oxaliplatin 1157Capecitabine 1140Fluorouracil 1059Dexamethasone 971Rituximab 918Nivolumab 908Magnetic Resonance Spectroscopy 858Etoposide 839Doxorubicin 823Drug Therapy 789Radiosurgery 774Irinotecan 774Cytarabine 736fludarabine 714Leucovorin 674Lenalidomide 608fludarabine phosphate 564Temozolomide 552Filgrastim 540Radiation 539Cetuximab 535

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Interventional × repotrectinib × Clear all
NCT06552234 2026-04-13

REPOROS

Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer

Phase 2 Recruiting
30 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05004116 2026-03-04

A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Recruiting
77 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT06315010 2026-02-25

REPOSE

MedSIR

Phase 2 Recruiting
20 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06408168 2026-01-05

Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)

M.D. Anderson Cancer Center

Phase 2 Terminated
6 enrolled

Carcinoma, Lobular

NCT04772235 2024-04-03

TOTEM

Instituto Oncológico Dr Rosell

Phase 1 Recruiting
32 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡